What is Leerink Partnrs’ Forecast for GPCR FY2025 Earnings?

Structure Therapeutics Inc. (NASDAQ:GPCR) – Investment analysts at Leerink Partnrs dropped their FY2025 earnings estimates for shares of Structure Therapeutics in a research note issued to investors on Thursday, May 8th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings per share of $1.78 for the year, down from their previous forecast of $1.80. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share. Leerink Partnrs also issued estimates for Structure Therapeutics’ FY2029 earnings at $0.97 EPS.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03).

GPCR has been the subject of several other reports. HC Wainwright decreased their price objective on shares of Structure Therapeutics from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Monday. Citigroup assumed coverage on shares of Structure Therapeutics in a research report on Friday, May 2nd. They issued a “buy” rating and a $60.00 price objective for the company. Finally, William Blair assumed coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an “outperform” rating for the company. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $78.00.

Structure Therapeutics Stock Down 3.7%

Shares of Structure Therapeutics stock opened at $24.62 on Monday. The firm has a market capitalization of $1.41 billion, a P/E ratio of -33.27 and a beta of -1.69. The company has a 50 day moving average price of $20.98 and a 200 day moving average price of $26.77. Structure Therapeutics has a 52 week low of $13.22 and a 52 week high of $62.74.

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors have recently made changes to their positions in the company. Virtus ETF Advisers LLC increased its holdings in shares of Structure Therapeutics by 25.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock valued at $61,000 after purchasing an additional 455 shares in the last quarter. Geode Capital Management LLC grew its stake in Structure Therapeutics by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 45,705 shares of the company’s stock valued at $1,240,000 after acquiring an additional 480 shares during the period. ANTIPODES PARTNERS Ltd grew its stake in Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock valued at $28,000 after acquiring an additional 553 shares during the period. LPL Financial LLC grew its stake in Structure Therapeutics by 6.0% in the 4th quarter. LPL Financial LLC now owns 11,485 shares of the company’s stock valued at $311,000 after acquiring an additional 646 shares during the period. Finally, Envestnet Asset Management Inc. grew its stake in Structure Therapeutics by 12.9% in the 4th quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company’s stock valued at $201,000 after acquiring an additional 843 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.